Clinical trial registry record

Mesenchymal Stem Cells for The Treatment of Frailty Syndrome

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 4, 2023.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04914403
Last registry update
December 4, 2023
Status
Unknown
Phase
Phase 1
Sponsor
Meridigen Biotech Co., Ltd.
Enrollment
6
Countries
Taiwan
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NA · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
6
Population
ALL · 60 Years to 85 Years
Duration
2021-09-01 to 2025-07-01
Intervention
UMC119-06-05
Comparator
Not reported
Outcomes measured
The incidence and frequency of adverse events related to administration of UMC119-06-05. — 3 months from the day of adm…; Changes in exercise performance using 6-min walk test (6MWT). — From baseline up to 360 days after administration.; Changes in grip strength. — From baseline up to 360 days after administration.; Changes in quality of life measured by change in SF12 (12-Item Short Form). — From baseline up to 360 days after admini…; Changes in physical activity using International Physical Activity Questionnaire (IPAQ) questionnaire — From baseline u…; Changes in Forced Expiratory Volume in One Second (FEV1). — From baseline up to 360 days after administration.; Changes in Clinical Frailty Scale. — From baseline up to 360 days after administration.
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Frailty · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
  • Stem cells · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

frailtystem cells
Read the original source →Export JSON